Acute statin treatment in reducing risk after acute coronary syndrome: theMIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial

Citation
Ch. Ahsan et al., Acute statin treatment in reducing risk after acute coronary syndrome: theMIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial, CURR OPIN C, 16(6), 2001, pp. 390-393
Citations number
22
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
CURRENT OPINION IN CARDIOLOGY
ISSN journal
0268-4705 → ACNP
Volume
16
Issue
6
Year of publication
2001
Pages
390 - 393
Database
ISI
SICI code
0268-4705(200111)16:6<390:ASTIRR>2.0.ZU;2-#
Abstract
Three-hydroxy-3methyl-glutaryl-CoA (HMG-CoA) reductase inhibitors (statins) reduce coronary events and death in both primary and secondary prevention trials, In these trials benefit did not appear for years after randomizatio n [1 (..),2,3]. It is noteworthy that these trials did not include patients with recent myocardial infarctions or unstable angina. It is well known th at mortality and recurrent ischemic events rates are the highest in the ear ly period after acute coronary syndromes [4,5,6]. Favorable physiologic eff ects of statins have been described within a few weeks of exposure to the s tatin in a number of experimental studies [7-10]. The Myocardial Ischemia R eduction with Aggressive Cholesterol Lowering (MIRACL) study [11] was desig ned to bridge the gap between primary and secondary prevention trials and s pecifically included patients with unstable angina or non-ST elevation myoc ardial infarction.